IP Library Granted Patent US 6,844,000
Granted Patent B2
US 6,844,000 · App. 10/313,332 · Granted Jan 18, 2005

Use of Parapox B2L protein to treat cancer and modify immune responses

Assignee: Bayer Pharmaceuticals Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,844,000
App. No.
10/313,332
Granted
Jan 18, 2005
Kind
B2
Abstract

A purified Parapoxvirus ovis envelope protein termed “B2L” can be used as a monotherapeutic agent. B2L protein also can be used in screening methods to identify potential therapeutic agents for modulating a subject's immune response to the B2L protein.

Claims (6)

1. A method of treating a patient having a cell proliferative disorder, comprising the step of:

administering to the patient an effective amount of a purified and isolated B2L viral envelope protein of a Parapox virus, whereby symptoms of the patient's cell proliferative disorder are ameliorated.

2. The method of claim 1 wherein the B2L protein is administered systemically.

3. The method of claim 1 wherein the B2L protein is injected into a tumor or dysplastic lesion.

4. A method of enhancing an immune response to endogenous antigens associated with a cell proliferative disorder, comprising the step of:

administering to a subject in need thereof an effective amount of a purified and isolated B2L viral envelope protein of a Parapox virus, whereby the B2L viral envelope protein enhances the immune response to the endogenous antigens.

Continuity (2)
Provisional Application 6033669400 · Dec 7, 2001
Related Publication 20030109483A1 · Jun 12, 2003